Squamous Cell Neoplasms (Squamous Cell Cancer)

Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.

Also Known As:

Squamous Cell Cancer; Neoplasms, Squamous Cell; Cancer, Squamous Cell; Cancers, Squamous Cell; Cell Cancer, Squamous; Cell Cancers, Squamous; Cell Neoplasm, Squamous; Cell Neoplasms, Squamous; Neoplasm, Squamous Cell; Squamous Cell Cancers; Squamous Cell Neoplasm

Networked: 2195 relevant articles (108 outcomes, 400 trials/studies)

Relationship Network

Disease Context: Research Results

Neoplasms: 1324753
- Neoplasms by Histologic Type: 2
  - Glandular and Epithelial Neoplasms: 439
    - Squamous Cell Neoplasms: 2195

Related Diseases

1.	Neoplasms (Cancer)
2.	Squamous Cell Carcinoma of Head and Neck
3.	Adenocarcinoma
4.	Neoplasm Metastasis (Metastasis)
5.	Lymphatic Metastasis

Experts

1.	Fury, Matthew G: 10 articles (10/2020 - 01/2011)
2.	Licitra, Lisa: 9 articles (12/2019 - 01/2003)
3.	Forastiere, Arlene A: 9 articles (03/2016 - 10/2002)
4.	Luo, He-San: 8 articles (10/2021 - 12/2017)
5.	Harrington, Kevin J: 8 articles (03/2020 - 02/2009)
6.	Pfister, David G: 8 articles (01/2018 - 01/2011)
7.	Psyrri, Amanda: 8 articles (06/2014 - 02/2005)
8.	Li, Xu-Yuan: 7 articles (06/2022 - 12/2017)
9.	Yu, Jinming: 7 articles (04/2022 - 08/2006)
10.	Wang, Qifeng: 7 articles (12/2021 - 03/2013)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Squamous Cell Neoplasms:

1.	Cisplatin (Platino)FDA LinkGeneric 04/01/2016 - "Cisplatin based chemoradiation is effective for treating HPV/p16 + pelvic squamous cell cancers of unknown primary as long as the mass, regional lymph nodes and high risk pelvic primary sites are adequately covered." 07/01/1984 - "A phase I-II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck." 01/01/2022 - "CircGOT1 promotes cell proliferation, mobility, and glycolysis-mediated cisplatin resistance via inhibiting its host gene GOT1 in esophageal squamous cell cancer." 01/01/2019 - "High-dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer (LAHNSCC) patients. " 10/01/2018 - "Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). "
2.	Fluorouracil (Carac)FDA LinkGeneric 11/01/1999 - "An orthotopic model of squamous cell cancer of the head and neck was used in vivo to study the CD/5-FC system both alone and with concurrent radiation due to the radiosensitizing properties that 5-FU generates in situ. " 01/01/2012 - "Low-dose continuous infusional PTX over 16-hours and 5-fu over 24-hours is a promising regimen with good tolerability in treating patients with advanced esophageal squamous cell cancer." 01/01/1992 - "Intra-arterial versus intravenous 5-fluorouracil infusion was compared in a naturally occurring, auricular epidermal squamous cell cancer in sheep. " 05/01/2019 - "In our study, we evaluated the effects of combining EGCG with 5-fluorouracil (5-FU) and radiotherapy on oral squamous cell cancer. " 02/01/1991 - "A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck."
3.	Cetuximab (Erbitux)FDA Link 10/01/2021 - "A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study." 11/01/2012 - "A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer." 01/01/2012 - "This current study evaluated eight cases of locally advanced and refractory basal cell or squamous cell cancers which were treated with cetuximab. " 01/01/2023 - "Retracted: FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer." 01/01/2022 - "FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer."
4.	ErbB Receptors (EGF Receptor)IBA 05/26/2019 - "Lung squamous cell cancer (LSCC) rarely harbors epidermal growth factor receptor (EGFR) mutations, even much rarer for acquired T790M mutation. " 01/01/2019 - "In head and neck squamous cell cancer, the human epidermal growth factor receptor 1 (EGFR) is the dominant signaling molecule among all members of the family. " 12/01/2015 - "The epidermal growth factor receptor (EGFR) is overexpressed in more than 80% of squamous cell cancers of the head and neck (SCCHN). " 05/01/2015 - "Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung." 05/01/2009 - "[Relation between epidermal growth factor receptor (EGFR) and p53 expression and radiocurability of laryngeal squamous cell cancer]."
5.	Irinotecan (Camptosar)FDA LinkGeneric 05/01/2004 - "The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11." 07/01/2003 - "CPT-11 as single-agent therapy is modestly effective against squamous cell cancer of the esophagus." 09/01/2017 - "The aim of the present study was to assess the feasibility and efficacy of irinotecan and cisplatin in the management of patients with vaginal squamous cell cancer (SCC). " 12/01/2001 - "In this study, we aim to evaluate the effects of CPT-11 on esophageal squamous cell cancers (ESCC) and to determine the correlation between the effects and the levels of Topo I expression. " 05/01/2003 - "These findings suggest that the combination chemotherapy with CPT-11 and nedaplatin for squamous cell cancer of uterine cervix is very useful in clinical practice. "
6.	Paclitaxel (Taxol)FDA LinkGeneric 04/01/1999 - "Because of its inherent activity against squamous cell cancer of the head and neck and its radiation-sensitizing properties, paclitaxel may be a valuable agent in the treatment of this patient population. " 08/01/1997 - "An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix." 04/01/2015 - "Paclitaxel (PTX) is broadly considered the drug of choice for treating human esophageal squamous cell cancer (ESCC). " 12/01/2011 - "Paclitaxel, a microtubule-stabilizing chemotherapeutic agent, has established clinical activity in squamous cell cancer of the head and neck. " 04/01/2007 - "Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter. "
7.	Proteins (Proteins, Gene)FDA Link 06/01/2019 - "The aim of our study was to examine the protein expression of PD-L1 and PD-1 in squamous cell cancer of the vulva, its correlations with clinicopathologic features and prognostic value. " 01/01/2019 - "Our previous studies have shown that low level of PDHA1 protein expression in esophageal squamous cell cancer (ESCC) was correlated with poor prognosis. " 09/01/2018 - "To evaluate the expressions of p16CDKN2A and TGF- β1 an immunohistochemical study of both proteins in 75 cervical tissues (24 CIN I, 17 CIN II, 15 CIN III and 19 squamous cell cancer) was performed. " 01/01/2011 - "The aim of this study is to investigate the expression of the chromosomal passenger protein Aurora B and its activated (phosphorylated) form in a large series of human oral squamous cell cancers (OSCC) and to evaluate its clinical and prognostic significance. " 03/01/2004 - "The aim of our study was to analyze the relationship between genetic changes leading to inactivation of the CDKN2A gene and subsequent alteration of protein expression in squamous cell cancer of the larynx (SCCL) in connection with the clinical and histopathological course of the disease. "
8.	Biomarkers (Surrogate Marker)IBA 01/01/2016 - "Identification and development of new biomarkers could be beneficial for diagnosis and prognosis of esophageal squamous cell cancer (ESCC) patients. " 01/01/2015 - "Expression of KRT13, FAIM2 and CYP2W1 appears to be influenced by risk habits, thus exploring the associations of these genes in oral squamous cell cancer (OSCC) with risk habits, clinico-pathological parameters and patient survival may be beneficial in identifying relevant biomarkers with different oncogenic pathways. " 01/01/2023 - "Cell Cycle-Related Gene SPC24: A Novel Potential Diagnostic and Prognostic Biomarker for Laryngeal Squamous Cell Cancer." 10/28/2021 - "At the time of diagnosis, more than 50% of patients with oral squamous cell cancers (OSCC) had advanced disease, indicating the lack of availability of early detection and risk assessment biomarkers. " 10/28/2021 - "A systematic review of proteomic biomarkers in oral squamous cell cancer."
9.	Docetaxel (Taxotere)FDA Link 06/01/2002 - "Preclinical data indicate that docetaxel is a potent radiosensitizer and its initial evaluation with concurrent radiation in patients with locally advanced unresectable squamous cell cancer of the head and neck suggests feasibility. " 06/01/2002 - "The activity of docetaxel (Taxotere) as a single agent (overall response rates, 24%-45%) in the treatment of patients with recurrent squamous cell cancer of the head and neck has resulted in the investigation of docetaxel-based doublet and triplet combinations in both the recurrent and neoadjuvant settings. " 06/01/2002 - "The role of docetaxel in the management of squamous cell cancer of the head and neck." 05/01/2002 - "Single-agent docetaxel is known to induce a response in 22-45% of patients with recurrent squamous cell cancer of the head and neck. " 02/01/2001 - "Single-agent docetaxel induces a response in 21-42% of patients with recurrent squamous cell cancer of the head and neck (SCCHN). "
10.	DNA (Deoxyribonucleic Acid)IBA 12/01/2015 - "The presence of human papillomavirus (HPV) DNA in oropharyngeal squamous cell cancer (OPSCC) tissue appears to be a strong predictor of improved prognosis, but this observation has not been explored in a population-based sample with generalisable findings. " 12/01/2017 - "Primary study outcomes are (i) prevalence of oncogenic HPV DNA in an oral rinse and gargle sample, and (ii) incident oropharyngeal squamous cell cancer. " 10/06/2017 - "The application of DNA targeted agents in head and neck squamous cell cancer showed promising preclinical results which are translated to multiple ongoing clinical trials, although no FDA approval has emerged yet. " 03/01/2013 - "This study enrolled 73 Japanese patients classified with Stage IIA-IV thoracic esophageal squamous cell cancer, and also investigated their CRP genetic polymorphisms using DNA extracted from their peripheral blood. " 11/01/2004 - "While evaluating the validity of using normal human mucosal cells from the upper aerodigestive tract as diploid standards for DNA content studies of squamous cell cancer of head and neck by flow cytometry, pseudoaneuploidy was frequently detected. "

Therapies and Procedures

1.	Radiotherapy 12/01/2022 - "Definitive radiation therapy with dose escalation is beneficial for patients with squamous cell cancer of the esophagus." 10/01/2019 - "Recent advances in radiation technology has allowed to significantly reduce toxicity and improve the efficacy of radical radiotherapy in head and neck and oral squamous cell cancers. " 01/01/2017 - "Although treatment paradigms have not changed significantly, radiotherapy, surgery, and imaging techniques have improved, leading us to investigate oncologic and survival outcomes for oral cavity squamous cell cancer (OCSCC) patients treated with surgery followed by postoperative IMRT. " 11/01/2011 - "Altered fractionated radiotherapy (RT) has been shown to improve locoregional control (LRC) and overall survival (OS) in squamous cell cancer of the head and neck (SCCHN). " 01/29/2018 - "This study aimed to clarify the efficacy of additional radiotherapy following ESD for esophageal squamous cell cancer involving T1a-MM or T1b-SM1. "
2.	Drug Therapy (Chemotherapy) 08/01/1979 - "Complete remission of a squamous cell cancer of the mandible by chemotherapy. " 12/01/1978 - "Until chemotherapy is proved more effective in the initial management of squamous cell cancer of the mouth and throat, radiation and surgery will remain the principal treatment modalities. " 05/01/2006 - "Because of the low efficacy of the present chemotherapy regimens, one should follow new strategies, comparable to those initiated for squamous cell cancer of other organs." 11/01/1985 - "Recent studies have shown improved efficacy of chemotherapy in patients with advanced squamous-cell cancer of the head and neck. " 07/01/2021 - "In our previous study, missense mutations in the Notch1 gene were found in chemotherapy-resistant esophageal squamous cell cancer (ESCC) patients. "
3.	Therapeutics 09/01/2015 - "We reviewed the records of 783 cervical squamous cell cancer patients who underwent primary therapy and showed complete remission at our institution between January 2000 and April 2014. " 03/01/2020 - "Endoscopic resection (ER) combined with adjuvant therapy appears to be a new treatment for esophageal squamous cell cancers (ESCC) invading to deep mucosa (pT1a-m3) or submucosa (pT1b). " 10/01/2022 - "Despite 3-year survival being used as a primary endpoint in some randomized controlled trials (RCTs), limited evidence supports the use of intermediate endpoints to evaluate the effect of new therapies in esophageal squamous cell cancer (ESCC). " 08/15/2013 - "Recent studies have shown that the incidence of squamous cell cancer of the anus (SCCA) has increased in the combined antiretroviral therapy (cART) era. " 11/01/2023 - "Oral metronomic therapy as a resource-adaptive palliative strategy for recurrent/metastatic head and neck squamous cell cancers."
4.	Chemoradiotherapy 01/01/2018 - "Chemoradiotherapy (CRT) has improved organ preservation or overall survival (OS) of locoregionally advanced head and neck squamous cell cancer (LAHNSCC), but in clinical trials of conventional CRT, increasing CRT intensity has not been shown to improve OS. " 01/01/2022 - "This study aimed to assess the role of pretreatment FA score in predicting the therapeutic efficacy of concurrent radiochemotherapy for patients with esophageal squamous cell cancer. " 01/01/2018 - "The aim of this study was to assess the difference (Δ) in neutrophil to lymphocyte ratio (NLR), before and after chemoradiotherapy, as a predictor of treatment response and a prognostic factor for recurrence and disease-free survival in patients with esophageal squamous cell cancer treated with chemoradiotherapy with or without surgery. " 10/20/2017 - "Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study." 02/01/2016 - "In the present study, we experimentally investigated the radio-enhancing effects of various concentrations of DTX against esophageal squamous cell cancer (ESCC); KES cells were used for in vitro confirmation of the effective administration schedule for DTX in chemoradiotherapy involving ESCC. "
5.	Neoadjuvant Therapy 07/01/2016 - "In conclusions, prechemotherapy neutrophil to lymphocyte ratio is an independent prognostic factor for OS in patients with advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy, and, as an adverse prognostic predictor, increased prechemotherapy neutrophil to lymphocyte ratio is superior to platelet to lymphocyte ratio. " 01/01/2022 - "Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus." 01/01/2022 - "Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus-Reply." 10/01/2021 - "To compare short-term outcomes between two- vs. three courses of neoadjuvant chemotherapy (NAC) to clarify the optimal treatment for esophageal squamous cell cancer (ESCC) in a multicenter, randomized, phase II trial. " 03/01/2016 - "We included in the study 190 patients with bulky stage Ib2 or IIa cervical squamous cell cancer, who underwent neoadjuvant chemotherapy followed by surgery. "